Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Correctors of the Major Cystic Fibrosis Mutant Interact through Membrane-Spanning Domains.

Laselva O, Molinski S, Casavola V, Bear CE.

Mol Pharmacol. 2018 Jun;93(6):612-618. doi: 10.1124/mol.118.111799. Epub 2018 Apr 4.

PMID:
29618585
2.

Comprehensive mapping of cystic fibrosis mutations to CFTR protein identifies mutation clusters and molecular docking predicts corrector binding site.

Molinski SV, Shahani VM, Subramanian AS, MacKinnon SS, Woollard G, Laforet M, Laselva O, Morayniss LD, Bear CE, Windemuth A.

Proteins. 2018 Aug;86(8):833-843. doi: 10.1002/prot.25496. Epub 2018 Apr 10.

PMID:
29569753
3.

Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics.

Hernandez JJ, Pryszlak M, Smith L, Yanchus C, Kurji N, Shahani VM, Molinski SV.

Front Oncol. 2017 Nov 14;7:273. doi: 10.3389/fonc.2017.00273. eCollection 2017. Review.

4.

The Antiretroviral Agent Nelfinavir Mesylate: A Potential Therapy for Systemic Sclerosis.

Sanchez CG, Molinski SV, Gongora R, Sosulski M, Fuselier T, MacKinnon SS, Mondal D, Lasky JA.

Arthritis Rheumatol. 2018 Jan;70(1):115-126. doi: 10.1002/art.40326. Epub 2017 Dec 8.

PMID:
28940894
5.

Orkambi® and amplifier co-therapy improves function from a rare CFTR mutation in gene-edited cells and patient tissue.

Molinski SV, Ahmadi S, Ip W, Ouyang H, Villella A, Miller JP, Lee PS, Kulleperuma K, Du K, Di Paola M, Eckford PD, Laselva O, Huan LJ, Wellhauser L, Li E, Ray PN, Pomès R, Moraes TJ, Gonska T, Ratjen F, Bear CE.

EMBO Mol Med. 2017 Sep;9(9):1224-1243. doi: 10.15252/emmm.201607137.

6.

Phenotypic profiling of CFTR modulators in patient-derived respiratory epithelia.

Ahmadi S, Bozoky Z, Di Paola M, Xia S, Li C, Wong AP, Wellhauser L, Molinski SV, Ip W, Ouyang H, Avolio J, Forman-Kay JD, Ratjen F, Hirota JA, Rommens J, Rossant J, Gonska T, Moraes TJ, Bear CE.

NPJ Genom Med. 2017 Apr 14;2:12. doi: 10.1038/s41525-017-0015-6.

7.

Biophysical Approaches Facilitate Computational Drug Discovery for ATP-Binding Cassette Proteins.

Molinski SV, Bozóky Z, Iram SH, Ahmadi S.

Int J Med Chem. 2017;2017:1529402. doi: 10.1155/2017/1529402. Epub 2017 Mar 19. Review.

8.

Computational proteome-wide screening predicts neurotoxic drug-protein interactome for the investigational analgesic BIA 10-2474.

Molinski SV, Shahani VM, MacKinnon SS, Morayniss LD, Laforet M, Woollard G, Kurji N, Sanchez CG, Wodak SJ, Windemuth A.

Biochem Biophys Res Commun. 2017 Jan 29;483(1):502-508. doi: 10.1016/j.bbrc.2016.12.115. Epub 2016 Dec 20.

PMID:
28007597
9.

Attenuation of Phosphorylation-dependent Activation of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) by Disease-causing Mutations at the Transmission Interface.

Chin S, Yang D, Miles AJ, Eckford PD, Molinski S, Wallace BA, Bear CE.

J Biol Chem. 2017 Feb 3;292(5):1988-1999. doi: 10.1074/jbc.M116.762633. Epub 2016 Dec 21.

10.

The investigational Cystic Fibrosis drug Trimethylangelicin directly modulates CFTR by stabilizing the first membrane-spanning domain.

Laselva O, Molinski S, Casavola V, Bear CE.

Biochem Pharmacol. 2016 Nov 1;119:85-92. doi: 10.1016/j.bcp.2016.09.005. Epub 2016 Sep 8.

PMID:
27614011
11.

Facilitating Structure-Function Studies of CFTR Modulator Sites with Efficiencies in Mutagenesis and Functional Screening.

Molinski SV, Ahmadi S, Hung M, Bear CE.

J Biomol Screen. 2015 Dec;20(10):1204-17. doi: 10.1177/1087057115605834. Epub 2015 Sep 18.

PMID:
26385858
12.

Sphingosine-1-Phosphate Is a Novel Regulator of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activity.

Malik FA, Meissner A, Semenkov I, Molinski S, Pasyk S, Ahmadi S, Bui HH, Bear CE, Lidington D, Bolz SS.

PLoS One. 2015 Jun 16;10(6):e0130313. doi: 10.1371/journal.pone.0130313. eCollection 2015.

13.

The major cystic fibrosis causing mutation exhibits defective propensity for phosphorylation.

Pasyk S, Molinski S, Ahmadi S, Ramjeesingh M, Huan LJ, Chin S, Du K, Yeger H, Taylor P, Moran MF, Bear CE.

Proteomics. 2015 Jan;15(2-3):447-61. doi: 10.1002/pmic.201400218. Epub 2014 Dec 17.

PMID:
25330774
14.

VX-809 and related corrector compounds exhibit secondary activity stabilizing active F508del-CFTR after its partial rescue to the cell surface.

Eckford PD, Ramjeesingh M, Molinski S, Pasyk S, Dekkers JF, Li C, Ahmadi S, Ip W, Chung TE, Du K, Yeger H, Beekman J, Gonska T, Bear CE.

Chem Biol. 2014 May 22;21(5):666-78. doi: 10.1016/j.chembiol.2014.02.021. Epub 2014 Apr 10.

15.

Genetic, cell biological, and clinical interrogation of the CFTR mutation c.3700 A>G (p.Ile1234Val) informs strategies for future medical intervention.

Molinski SV, Gonska T, Huan LJ, Baskin B, Janahi IA, Ray PN, Bear CE.

Genet Med. 2014 Aug;16(8):625-32. doi: 10.1038/gim.2014.4. Epub 2014 Feb 20.

PMID:
24556927
16.

Conformational defects underlie proteasomal degradation of Dent's disease-causing mutants of ClC-5.

D'Antonio C, Molinski S, Ahmadi S, Huan LJ, Wellhauser L, Bear CE.

Biochem J. 2013 Jun 15;452(3):391-400. doi: 10.1042/BJ20121848.

PMID:
23566014
17.

Functional Rescue of F508del-CFTR Using Small Molecule Correctors.

Molinski S, Eckford PD, Pasyk S, Ahmadi S, Chin S, Bear CE.

Front Pharmacol. 2012 Sep 26;3:160. doi: 10.3389/fphar.2012.00160. eCollection 2012.

18.

Identification and validation of hits from high throughput screens for CFTR modulators.

Pasyk S, Molinski S, Yu W, Eckford PD, Bear CE.

Curr Pharm Des. 2012;18(5):628-41. Review.

PMID:
22229556
19.

Mammalian multidrug-resistance proteins (MRPs).

Slot AJ, Molinski SV, Cole SP.

Essays Biochem. 2011 Sep 7;50(1):179-207. doi: 10.1042/bse0500179. Review.

PMID:
21967058
20.

Platelet and red blood cell phagocytosis kinetics are differentially controlled by phosphatase activity within mononuclear cells.

Aslam R, Kim M, Speck ER, Seetanah AC, Molinski S, Freedman J, Semple JW.

Transfusion. 2007 Nov;47(11):2161-8.

PMID:
17958546

Supplemental Content

Loading ...
Support Center